Guizhou Yibai Pharmaceutical Co Ltd (600594) — Cash Flow-to-Debt Ratio
Guizhou Yibai Pharmaceutical Co Ltd (600594) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥33.28 Million could theoretically repay 0% of its total liabilities (CN¥1.32 Billion) in one year. See 600594 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Guizhou Yibai Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Guizhou Yibai Pharmaceutical Co Ltd across 24 annual periods. Also explore Guizhou Yibai Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Guizhou Yibai Pharmaceutical Co Ltd (2002–2025)
Year-by-year debt coverage analysis for Guizhou Yibai Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see 600594 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥256.71 Million | CN¥1.17 Billion | ▲ +276.8% |
| 2024 | 0.06x | CN¥86.87 Million | CN¥1.49 Billion | ▼ -75.7% |
| 2023 | 0.24x | CN¥377.61 Million | CN¥1.58 Billion | ▲ +16.1% |
| 2022 | 0.21x | CN¥345.30 Million | CN¥1.68 Billion | ▼ -66.8% |
| 2021 | 0.62x | CN¥934.21 Million | CN¥1.51 Billion | ▲ +198.4% |
| 2020 | 0.21x | CN¥366.66 Million | CN¥1.76 Billion | ▲ +8.6% |
| 2019 | 0.19x | CN¥362.71 Million | CN¥1.89 Billion | ▲ +129.1% |
| 2018 | 0.08x | CN¥214.30 Million | CN¥2.56 Billion | ▼ -68.7% |
| 2017 | 0.27x | CN¥681.78 Million | CN¥2.55 Billion | ▲ +68.1% |
| 2016 | 0.16x | CN¥380.62 Million | CN¥2.40 Billion | ▼ -43.6% |
| 2015 | 0.28x | CN¥573.68 Million | CN¥2.04 Billion | ▲ +7.7% |
| 2014 | 0.26x | CN¥541.58 Million | CN¥2.07 Billion | ▼ -42.5% |
| 2013 | 0.46x | CN¥577.24 Million | CN¥1.27 Billion | ▲ +15.6% |
| 2012 | 0.39x | CN¥288.01 Million | CN¥731.33 Million | ▼ -5.7% |
| 2011 | 0.42x | CN¥277.83 Million | CN¥665.51 Million | ▲ +148.6% |
| 2010 | 0.17x | CN¥115.66 Million | CN¥688.82 Million | ▼ -7.7% |
| 2009 | 0.18x | CN¥103.88 Million | CN¥571.26 Million | ▼ -40.4% |
| 2008 | 0.30x | CN¥189.26 Million | CN¥620.62 Million | ▲ +1458.1% |
| 2007 | 0.02x | CN¥11.94 Million | CN¥610.24 Million | ▼ -88.5% |
| 2006 | 0.17x | CN¥95.77 Million | CN¥562.27 Million | ▲ +539.5% |
| 2005 | 0.03x | CN¥17.38 Million | CN¥652.65 Million | ▲ +121.5% |
| 2004 | -0.12x | CN¥-44.80 Million | CN¥361.10 Million | ▼ -137.0% |
| 2003 | 0.34x | CN¥92.10 Million | CN¥274.93 Million | ▼ -20.3% |
| 2002 | 0.42x | CN¥73.46 Million | CN¥174.87 Million | — |